Between January 2010 and September 2010 , 700 CHD patients with DM who were aged 65 years and undergoing coronary angiography at An Zhen Hospital ( Beijing , China ) were recruited and prospectively randomized to receive trimetazidine ( 20 mg three times daily ) or placebo after DES implantation as an addition to conventional CHD treatment .